newsfilter
← Latest News
ACCESS Newswire·

Jaguar Health Reports Second Quarter 2026 Financials

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results